Robinetin inhibits osteosarcoma proliferation and migration, acting via the Slug/Twist signaling axis

Area of Science:

• Oncology
• Pharmacology
• Biochemistry

Background:

• Osteosarcoma is the most common primary bone cancer in young individuals.
• Current treatments have plateaued survival rates, necessitating novel therapeutic strategies.
• Flavonoids possess antioxidant, anti-inflammatory, and anticancer properties.

Purpose of the Study:

• To evaluate the therapeutic potential of five distinct flavonoids against osteosarcoma.
• To identify specific flavonoids effective against osteosarcoma cell lines.
• To investigate the synergistic effects of promising flavonoids with conventional chemotherapy.

Main Methods:

• In vitro screening of five flavonoids against four human osteosarcoma cell lines (MG-63, Saos-2, HOS, 143B).
• Assessment of cytotoxicity against healthy human lung fibroblasts (MRC-5) to determine selectivity.
• Evaluation of robinetin's synergistic effects with doxorubicin on 143B cell viability, migration, and metastasis-related gene expression.
• In vivo efficacy testing of robinetin using a chick chorioallantoic membrane xenograft model.

Main Results:

• Robinetin demonstrated the highest cytotoxicity against osteosarcoma cells, with minimal impact on healthy fibroblasts.
• Robinetin synergized with doxorubicin to decrease 143B cell viability and inhibit cell migration.
• Robinetin treatment led to the downregulation of key metastasis-related transcription factors: c-Jun, Snail, Slug, and Twist2.
• In vivo studies confirmed robinetin's ability to inhibit osteosarcoma tumor xenograft growth.

Conclusions:

• Robinetin exhibits significant therapeutic potential for osteosarcoma treatment.
• Robinetin demonstrates selective toxicity towards osteosarcoma cells.
• The combination of robinetin and doxorubicin may offer an enhanced therapeutic strategy.
• Robinetin represents a novel candidate for future osteosarcoma drug development.